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Abstract 
Human T cell leukemia virus type 1 (HTLV‑1) is an oncogenic retrovirus responsible for the development of adult T‑cell 
leukemia (ATL). Although HTLV‑1 harbors an oncogene, tax, that transforms T cells in vitro and induces leukemia in 
transgenic mice, tax expression is frequently disrupted in ATL, making the oncogenesis of ATL a bit mysterious. The 
HTLV‑1 bZIP factor (HBZ) gene was discovered in 2002 and has been found to promote T‑cell proliferation and cause 
lymphoma in transgenic mice. Thus HBZ has become a novel hotspot of HTLV‑1 research. This review summarizes the 
current findings on HBZ with a special focus on its potential links to the oncogenesis of ATL. We propose viewing HBZ 
as a critical contributing factor in ATL development.
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Background
Human T-cell leukemia virus type 1 (HTLV-1) is the first 
human retrovirus to have been identified (in the early 
1980s), and it was later demonstrated to be the causa-
tive agent of adult T-cell leukemia (ATL), an aggressive 
cancer of peripheral CD4 T cells [1, 2]. HTLV-1 is able to 
infect various cell types in vitro, yet the HTLV-1 provirus 
is predominantly detected in CD4 T cells in vivo [3]. The 
CD4 T cell tropism of HTLV-1 is likely due to selected 
expansion of infected CD4 T cells rather than a receptor 
preference, because the HTLV-1 receptor, glucose trans-
porter 1 (GLUT1) is ubiquitously expressed [4, 5].
The HTLV-1 provirus is 9  kb long and has multiple 
coding regions flanked by two identical 750-bp long ter-
minal repeats (LTRs) in the 5′ and 3′ ends (Fig. 1), both 
of which are composed of unique 3′ (U3), repeat (R) and 
unique 5′ (U5) regions. The 5′ LTR serves as the pro-
moter for all structural genes and most accessary and 
regulatory genes, including the gene for the transactiva-
tor Tax, which upregulates 5′ LTR activity by recruiting 
cAMP response element-binding protein (CREB) to three 
viral CREB-responsive element (vCRE) tandem repeats in 
the 5′ LTR [6]. Transcriptional coactivators such as CBP/
p300 and P/CAF are also recruited to vCRE by Tax [6]. 
The 3′ LTR is able to initiate transcription from the nega-
tive strand of the provirus and serves as the promoter for 
the only antisense transcript of the virus, HTLV-1 basic 
leucine zipper factor (HBZ) [7–9].
Although most HTLV-1 infected individuals remain 
lifelong asymptomatic carriers, approximately 5  % of 
them will develop ATL after a long latency of decades 
[10]. HTLV-1 also causes several inflammatory diseases 
such as uveitis, dermatitis and a neurodegenerative disor-
der called HTLV-1-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP) [11].
Review
The HBZ gene
Tax is of crucial importance for its unique ability to drive 
HTLV-1 replication and to immortalize T cells [12] and 
thus has long been thought to be the main causal factor 
of ATL. However, it has been reported that Tax expres-
sion is frequently inactivated in ATL cases by either abor-
tive mutations in the tax gene or DNA methylation of the 
5′ LTR [13–16]. In addition, a defective provirus with the 
5′ LTR partially or completely deleted has been found in 
up to 40 % of ATL cases [17, 18]. Host immunosurveil-
lance by cytotoxic T lymphocytes (CTLs) is thought to 
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be responsible for the loss of Tax expression, since Tax 
protein is a major target of CTLs [19]. In contrast to the 
5′ LTR, the 3′ LTR remains intact and non-methylated—
and the HBZ gene harbors no abortive mutations and 
is consistently expressed in ATL patients and HTLV-1 
infected individuals [18, 20, 21]. Furthermore, HBZ 
mRNA abundance positively correlates with HTLV-1 
proviral load in asymptomatic carriers (AC), HAM/TSP 
and ATL patients [22–24]. The distinct expression pat-
terns of HBZ and tax suggest that they have different 
roles in the course of HTLV-1 pathogenesis.
The HBZ gene has two transcription isoforms: an 
unspliced (usHBZ) form and a spliced (sHBZ) form. 
usHBZ was discovered in 2002 [8] and early publica-
tions on HBZ were exclusively based on usHBZ. The 
alternative transcript, sHBZ, was first reported in 2006 
[25–27]. These two transcripts have different 5′ untrans-
lated regions (UTRs) and differ slightly in the 5′ region 
of their coding sequences (CDS) (Fig.  1). Consequently, 
the usHBZ and sHBZ proteins have almost identi-
cal sequences except for the first several amino acids 
(MAAS for sHBZ and MVNFVSA for usHBZ). Previous 
studies have shown that usHBZ and sHBZ exhibit simi-
lar functions. However, since sHBZ is more abundantly 
expressed in infected cells [9, 22], current studies are 
mostly focused on sHBZ. This review mainly addresses 
the functions of sHBZ.
The transcription of sHBZ initiates from the U5 and R 
regions of the 3′ LTR [25, 27], and the whole 3′ LTR likely 
serves as a TATA-less promoter of sHBZ [9]. sHBZ tran-
scription terminates at a classical polyadenylation signal 
downstream [27]. Three vCRE [28] and three specificity 
protein 1 (Sp1) binding sites [9] have been discovered in 
the 3′ LTR, and they seem to be critical for its promoter 
activity. Due to the presence of vCRE, the activity of the 
3′ LTR is enhanced by Tax via a CREB-dependent mecha-
nism [28]. HBZ, by recruiting JunD to the Sp1 sites, also 
enhances the activity of the 3′ LTR [29].
It is interesting that the activity of the 3′ LTR seems to 
respond to some stimuli in an opposite way from that of 
the 5′ LTR. It has been reported that two Tax antagonis-
tic cellular proteins, TCF1 and LEF1, significantly inhibit 
Tax-mediated 5′ LTR activation but slightly enhance 3′ 
LTR activation [30]. In addition, valproic acid (VPA), a 
deacetylase inhibitor, is reported to have opposite effects 
on the 3′ and 5′ LTRs, in that it represses HBZ expression 
but increases Tax expression [31].
Functions of HBZ protein
HBZ is a nuclear protein [32–35] and comprises an acti-
vation domain (AD) in the N-terminus, a central domain 
(CD), and a basic leucine zipper (bZIP) domain in the 
C-terminus (Fig. 2). The N-terminus of HBZ was found 
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Fig. 1 HTLV‑1 provirus, mRNAs and proteins. HTLV‑1 provirus is shown on top in blue with both LTRs painted in brown. Below, the transcripts and 
proteins encoded by a complete HTLV‑1 provirus are shown. Sense transcripts are portrayed as black arrows with arrowheads pointing to the right, 
while antisense transcripts run in the opposite direction. Spliced exons are shown in solid black lines while introns are shown as dotted lines. Proteins 
derived from respective mRNAs are shown as empty squares
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DNA-binding domain of GAL4 and therefore termed AD 
[8]. Within the AD of HBZ, two LXXLL-like motifs have 
been identified and shown to bind to the KIX domain 
of CBP/p300 [36], well-known transcription coactiva-
tors that are involved in a variety of cellular functions 
[37]. These LXXLL motifs are also required for HBZ 
to activate TGF-β/Smad signaling, which is critical for 
HBZ-induced Foxp3 expression [38]. The bZIP domain 
enables HBZ to hetero-dimerize with cellular bZIP pro-
teins of the AP1 superfamily [39], such as CREB2 [8], 
c-Jun [40, 41], JunB [40], JunD [29, 42], CREB [43], MafB 
[44] and ATF3 [45] (Fig. 2). In most cases the HBZ/AP1 
hetero-dimerization impairs the association of AP1 pro-
teins with their responsive DNA elements [8, 40, 41, 43, 
44] but in some cases dimerization can instead result in 
enhanced DNA binding—as is the case for JunD [29, 42]. 
It should be noted that although HBZ protein is modified 
by phosphorylation, acetylation or methylation, a recent 
report demonstrates that none of these post-translational 
modifications likely affect its function [46].
HBZ and HTLV‑1 infectivity
When overexpressed, HBZ is found to repress the for-
mation of the transactivation complex composed of 
Tax, CREB, CBP/p300, P/CAF and vCRE and subse-
quent activation of the HTLV-1 5′ LTR in  vitro [6, 12] 
by hetero-dimerizing with CREB proteins via the bZIP 
domain [8, 40, 43] and interacting with CBP/p300 via 
the LXXLL motifs [36]. However, when HBZ expression 
was knocked out (KO) from an HTLV-1 infectious clone 
by introducing a premature stop codon (clone termed 
HBZ-KO), virus production was not affected [47, 48]. 
HBZ knockdown in an HTLV-1 infected cell line did not 
affect viral replication [49], suggesting a distinct effect of 
endogenous HBZ on viral infectivity. Interestingly, when 
this HBZ-KO HTLV-1 clone was used to infect rabbits, 
proviral copies were significantly suppressed, indicating a 
positive role of HBZ in HTLV-1 infectivity or prolifera-
tion of infected cells in  vivo [47]. In addition, the same 
HBZ-KO HTLV-1 clone has also been tested in a mon-
key infection model [48]. All four monkeys were suc-
cessfully infected, but it was very difficult to determine 
whether this mutant would demonstrate an impaired 
infectivity due to the lack of a wild-type HTLV-1 clone 
as control in the monkey experiments. Nevertheless, an 
intriguing finding, which was not observed in rabbits, 
is that the abortive mutations in the HBZ-KO HTLV-1 
clone gradually reverted to wild type as infection pro-
longed, until revertant clones with intact HBZ genes 
became dominant. This observation might imply a fairly 
stringent requirement for wild type HBZ in HTLV-1 
infection in monkeys, although it should be confirmed in 
larger number of monkeys. Therefore, despite inhibiting 
HTLV-1 replication in vitro, HBZ seems to be indispen-
sible for HTLV-1 infectivity or proliferation of infected 
cells in vivo.
HBZ maintains a persistent HTLV‑1 latent infection
Tax is known to activate various cellular signaling path-
ways including the well-known NFκB pathway [50]. 
In contrast, HBZ does not affect non-canonical NFκB 
pathway, and HBZ inhibits the canonical NFκB pathway 
by repressing the DNA-binding potential and inducing 
proteasomal degradation of p65 [51]. The significance 
of this function of HBZ was obscure until the recent dis-
covery that Tax-mediated NFκB hyperactivation leads to 
senescence in HeLa cells—senescence which is alleviated 
by HBZ because of its ability to inhibit canonical NFκB 
activation. HBZ completely abrogated canonical NFκB 
activation by Tax without affecting its activation of the 
5′ LTR, and thereby allowed cells to overcome Tax-trig-
gered senescence and grow continuously [52].
The proper expression of HTLV-1 structural proteins 
relies on Rex-mediated nuclear export of viral mRNAs 
[53]. In contrast, the nuclear export of accessory and 
regulatory viral mRNAs, especially HBZ, is Rex-inde-
pendent [54, 55]. Interestingly, HBZ can block the Rex-
mediated nuclear export of viral structural transcripts 




































Fig. 2 Cellular proteins that interact with HBZ. The three domains of 
sHBZ are portrayed as squares in three different colors while the cellular 
binding partners of HBZ are demonstrated as squircles with colors cor‑
responding to that of AD, CD or bZIP domain of HBZ that they inter‑
act with. Cellular proteins that bind to more than one domain of HBZ 
are painted in multiple colors whereas those lacking such information 
are painted in dark grey. The major pathways that these interactions 
have impact on, either positive (+) or negative (−), are noted close 
to respective cellular proteins while more detailed description can 
be found in the text. Some of the interactions are not discussed in 
the text due to space limitations, which include 26s proteasome [93], 
CENP‑B [94], C/EBPα [95] and IRF‑1 [96]. For Foxp3, HBZ enhances 
transcription from the Foxp3 promoter (Treg differentiation: diff.) 
while it suppresses function of Foxp3 (Treg function: func.)
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maintaining a latent HTLV-1 infection without the pro-
duction of virus particles. Thus HBZ does not support 
productive HTLV-1 replication, but rather appears to 
maintain HTLV-1 persistence by suppressing senescence 
and inducing viral latency.
HBZ promotes proliferation of T cells
Among the AP1 superfamily proteins that can interact 
with HBZ, ATF3 and JunD are upregulated at the tran-
scriptional level in ATL [45, 57]. ATF3 is a transcrip-
tion factor that belongs to the ATF/CREB family. ATF3 
has bimodal functions in oncogenesis, because on the 
one hand it activates p53 signaling and acts as a tumor 
suppressor, but on the other hand it is upregulated in 
some cancers and promotes proliferation [45]. Interest-
ingly, HBZ impedes the p53-enhancing function of ATF3 
that is deleterious to ATL development, but HBZ does 
not hinder the growth-promoting effect of ATF3 [45]. 
The expression of JunD is increased in cutaneous T-cell 
lymphomas as well as in ATL [58]. HBZ not only inter-
acts with JunD and enhances its transcriptional activ-
ity, but also induces JunD expression in NIH3T3 cells. 
Importantly, HBZ-induced cellular proliferation can be 
impaired by JunD knockdown, indicating that HBZ indi-
rectly promotes proliferation via JunD [29].
Two studies suggest that HBZ also employs certain 
autocrine/paracrine pathways to enhance ATL cell prolif-
eration [59, 60]. HBZ upregulates the transcription of the 
noncanonical Wnt ligand Wnt5a while suppressing the 
canonical Wnt pathway that is detrimental to ATL cell 
growth. Wnt5a enhances both proliferation and migra-
tion of ATL cells [59]. Recently another study showed 
that HBZ upregulates brain-derived neurotropic factor 
(BDNF) expression via enhancing its promoter activity 
[60]. Upregulation of BDNF and its receptor, tropomyo-
sin receptor kinase B (TrKB), further promotes ATL cell 
proliferation [60].
HBZ inhibits apoptosis and autophagy
HBZ hinders activation-induced cell death in T cells. 
The expression of Bim, a pro-apoptotic gene, is greatly 
suppressed by HBZ and is also inhibited in HTLV-1 
infected T-cell lines. Knockdown of HBZ increases Bim 
expression, indicating that Bim is a target of HBZ [61]. 
FoxO3a is an important transcription factor that controls 
the expression of Bim and FasL. Further investigation 
showed that HBZ forms a ternary complex with FoxO3a 
and 14-3-3. By doing so, HBZ impairs the DNA-binding 
ability of FoxO3a and also sequesters inactive phospho-
rylated FoxO3a in the nucleus, thereby repressing the 
transactivation of Bim and FasL by FoxO3a [61]. Interest-
ingly, FoxO3a is also a target of Tax in anti-apoptosis and 
CD4 T-cell persistence [62], suggesting an important role 
of FoxO3a in regulating apoptosis in HTLV-1 infected 
cells.
Autophagy is a natural cellular digestion mechanism 
that removes unnecessary or damaged cellular com-
ponents [63]. It can be routinely triggered by amino 
acid deprivation, which also inhibits the activity of the 
mammalian target of rapamycin (mTOR) complex 1 
(mTORC1) [63]. mTORC1 is a signaling complex of the 
mTOR pathway, which regulates cellular metabolism 
and promotes cell proliferation in response to proper 
environmental stimuli [63]. Autophagy and the mTOR 
pathway are inversely coupled, and mTOR inhibition has 
been shown to induce autophagy [63]. Recently, HBZ 
was reported to activate the mTOR pathway via inter-
acting with and inhibiting growth arrest and DNA dam-
age-inducible protein 34 (GADD34), a stress-induced 
GADD family protein that inhibits the mTOR pathway 
[64]. More importantly, starvation-induced autophagy 
was suppressed by HBZ, which might be due to its acti-
vation of the mTOR pathway [64]. However, more direct 
evidence is needed to prove this possibility. In addition, 
GADD34 itself is involved in the regulation of apop-
tosis [65], so it would be interesting to further evaluate 
the possible impact of HBZ/GADD34 interaction on 
apoptosis.
HBZ disrupts genomic integrity
Genomic instability is a hallmark of cancer, and various 
kinds of genetic alterations have been reported in ATL 
[21]. A recent study found that HBZ expression induces 
double strand breaks (DSBs) in transfected HeLa cells, 
and is the first to link HBZ to genomic instability [66]. 
Intriguingly, HBZ-induced DSBs are dependent on sev-
eral microRNAs (miR) that are HBZ-inducible, such as 
miR17 and miR21. miR17 and miR21 target and suppress 
the expression of OBFC2A, the gene that encodes hSSB2, 
a single-stranded DNA-binding protein that prevents 
genomic instability. Overexpression of OBFC2A counter-
acts the DNA-damaging effect of HBZ [66]. It is thus pro-
posed that HBZ disrupts host genomic integrity through 
this HBZ-microRNA-OBFC2A cascade.
Telomeres are chromosomal regions composed of 
tandem repeats of TTAGGG and are localized at chro-
mosomal ends [67]. It is well known that telomeres 
become shortened after each cell division, until cells 
reach a state of replication senescence known as the 
“Hayflick limit.” Telomeres can be replenished by telom-
erase, which contains an important catalytic unit called 
telomerase reverse transcriptase (TERT) whose activ-
ity is kept low in normal somatic cells [67]. In contrast, 
cancer cells often break the “Hayflick limit” by elevating 
TERT expression to allow sustained proliferation. HBZ 
has been reported to promote human TERT (hTERT) 
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expression via enhancing its promoter activity in associa-
tion with JunD [68]. The activities of two inhibitors of the 
hTERT promoter, TAL1 and menin, are also suppressed 
by HBZ [69, 70]. Elevation of hTERT levels by HBZ may 
allow sustained proliferation of ATL cells, which have 
been reported to overexpress hTERT [71, 72].
HBZ induces inflammation
HBZ-transgenic (Tg) mice, in which HBZ is expressed 
only in CD4+ T cells, frequently develop dermatitis, 
and some of HBZ-Tg mice develop lymphoma [73–75]. 
In HBZ-Tg mice, increased numbers of Foxp3+CD4+ 
T cells were found. This population contains regulatory 
T cells (Tregs), a T-cell subset known to suppress effec-
tor T cells [38]. HBZ induces T cells to become Tregs 
by enhancing the TGF-β/Smad pathway via forming a 
ternary complex with Smad3/p300 and thereby upregu-
lating expression of Foxp3, the TGF-β-inducible mas-
ter transcription factor of Tregs [38]. However, Foxp3 
expression is unstable in Foxp3+ T cells of HBZ-Tg mice, 
and thus Foxp3+ T cells convert to Foxp3− T cells with 
enhanced production of IFN-γ [74]. This enhanced pro-
duction of IFN-γ is associated with both inflammation 
and the development of lymphomas in HBZ-Tg mice; 
loss of IFN-γ suppresses both of these phenomena [75]. 
In addition, the ability to induce Treg differentiation and 
inflammation development is completely an intrinsic 
characteristic of HBZ, because even HBZ-Tg mice main-
tained in a germ-free environment had the same pheno-
type as those raised in a normal specific-pathogen-free 
environment [75], excluding the role of extrinsic factors 
such as the gut microbiota.
Another interesting finding is that HBZ-Tg mice 
exhibited impaired immune responses to herpes sim-
plex virus or Listeria monocytogenes infection compared 
to WT mice [76]. Th1 cytokine production was signifi-
cantly reduced in infected HBZ-Tg mice, an observation 
which seems attributable to HBZ-mediated NFAT and 
AP1 inhibition. The compromised immune response 
of HBZ-Tg mice to infections likely correlates with the 
observation that some ATL patients suffer from oppor-
tunistic infections and implies a role of HBZ in the 
impaired immunity of ATL patients [76].
HBZ protein is low immunogenic
Immunogenicity is the ability of a foreign antigen/epitope 
to provoke a cellular or humoral immune response in the 
host. It is a key issue in vaccine development that greatly 
affects vaccine efficiency. Among all HTLV-1 viral pro-
teins, HBZ likely has the lowest immunogenicity, because 
anti-HBZ antibodies could rarely be detected in HTLV-1 
infected individuals, whereas antibody responses to other 
viral antigens could be easily detected. Nevertheless, an 
HBZ-specific humoral response has been detected by a 
highly sensitive luciferase immunoprecipitation system 
(LIPS) [77, 78]. Interestingly, anti-HBZ serum from one 
HAM/TSP patient inhibited the proliferation of CD8 T 
cells from an HBZ-antibody-negative HAM/TSP patient 
[77]. However, whether anti-HBZ antibody is truly inhib-
itory to HBZ-expressing infected cells remains to be clar-
ified by future studies.
Compared to the anti-HBZ humoral response, HBZ-
specific cellular immunity has been studied more exten-
sively. Hilburn et al. [79] detected HBZ-specific CD4 or 
CD8 T cells in only about half of asymptomatic HTLV-1 
carriers and HAM/TSP patients tested and found that 
HBZ-specific CTLs are associated with low proviral load 
and asymptomatic carriage.
The low level of expression of HBZ protein in HTLV-1 
infected cells is one likely reason for the inefficiency of 
the specific immune response. In accordance with this 
notion, another study that compared the lysis of HTLV-1 
infected cells by HBZ- versus Tax-specific CTLs attrib-
uted the unsatisfactory lytic efficiency of HBZ-specific 
CTLs to inadequate presentation of HBZ epitopes [80]. 
Therefore, despite the fact that HLA I binding of HBZ 
provides the biggest protective/detrimental ratio as sug-
gested by in  vitro experiments and computational anal-
ysis [81], the relatively weak binding strength of HBZ 
epitopes to CTLs in  vitro as well as the low expression 
of HBZ protein in vivo might greatly hinder the ability of 
the host to mount a successful anti-HBZ CTL response. 
Nevertheless, a recent study suggests that mice and 
macaques that have been immunized by a recombinant 
vaccinia virus-based HBZ vaccine can successfully gen-
erate HBZ-specific CD4 and CD8 T-cell responses [82, 
83]. Importantly, anti-HBZ CTLs from immunized mice 
are protective when adoptively transferred to an HBZ-
induced ATL mouse model [83]. Furthermore, a candi-
date HBZ peptide (157-176 aa) was identified for future 
human vaccine development [83]. Nonetheless, low 
immunogenicity of HBZ likely facilitates infected cells’ 
evasion of immunosurveillance and perhaps contributes 
to the HTLV-1-mediated oncogenesis.
HBZ RNA is growth promoting and anti‑apoptotic
HBZ is unique in that it is the only HTLV-1 gene tran-
scribed from the antisense strand—a subtle mecha-
nism that avoids the use of the frequently disrupted or 
methylated 5′ LTR as its promoter and also evades host 
APOBEC3G-induced nonsense mutations [18, 20]. 
Intriguingly, HBZ RNA carries regulatory functions 
aside from the common protein-coding function. It has 
been reported that HBZ RNA itself supports the pro-
liferation of the IL-2-dependent T-cell line Kit225 cul-
tured at a suboptimal concentration of IL-2. The precise 
Page 6 of 9Ma et al. Retrovirology  (2016) 13:16 
mechanism is unclear but HBZ RNA likely achieves this 
by targeting E2F1 and upregulating its expression, as 
well as the expression of its downstream target genes, to 
enhance proliferation [25]. A recent study revealed that 
HBZ RNA also inhibits apoptosis in mouse CD4 T cells 
[84]. HBZ RNA increases the transcription of the anti-
apoptotic gene survivin, a fact which likely accounts for 
its anti-apoptotic effects. These two key functions of HBZ 
mRNA (proliferation-enhancing and anti-apoptotic) 
imply that HBZ might contribute to the oncogenesis of 
ATL in its RNA form as well. Since mRNAs ordinar-
ily localize to the cytoplasm for the sake of translation, 
whereas regulatory long noncoding RNAs (lncRNA) 
are found mostly in the nucleus [85, 86], the dominant 
nuclear localization of HBZ RNA reported in several 
studies [54, 55, 87] supports the regulatory role of HBZ 
RNA as well.
Antisense protein of HTLV‑2 (APH‑2)
HTLV-2 is a close relative of HTLV-1 that has not been 
linked to any diseases and thus is considered to be non-
pathogenic. HTLV-2 has also been reported to encode 
an antisense transcript termed APH-2 [88]. APH-2 has 
similar functions as HBZ such as inhibiting transcription 
from HTLV-2 5′ LTR and is dispensable for in vitro T-cell 
immortalization [89]. APH-2 demonstrates distinct 
activities as HBZ in modulating cellular pathways [90] 
whereas it lacks the ability to promote T-cell prolifera-
tion [91], which might contribute to the nonpathogenic 
nature of HTLV-2.
Perspective
It has been assumed as an oncogenesis model for HTLV-1 
that Tax initiates cellular transformation at an early stage, 
while HBZ maintains the transformed phenotype dur-
ing the late stage when Tax expression is absent or sup-
pressed. However, since HBZ expression has always been 
present regardless of early or late stage, it seems inac-
curate to attribute the first hit of oncogenesis solely to 
Tax. In fact, accumulating evidence now implies a criti-
cal role of HBZ throughout the course of HTLV-1 medi-
ated oncogenesis. As summarized above, HBZ has been 
found to carry a wide variety of functions that associate 
with seven out of ten cancer hallmarks (Fig. 3) [92]. If we 
exclude hallmarks like angiogenesis or invasion that are 
generally characteristics of solid cancers, then deregula-
tion of cellular energetics is the only hallmark yet to be 
associated with HBZ. Hence, despite the fact that HBZ 
has not been reported to associate directly with cellular 
transformation like Tax does, HBZ does seem to harbor 
the required potential to cause cancer. Tax and HBZ fre-
quently shows opposite effects on signaling pathways, 
suggesting that HBZ plays different roles in oncogenesis 
from Tax. Furthermore, given the fact that the HBZ gene 
is the only HTLV-1 gene present in all infected individu-
als, HBZ-targeting strategies are expected to serve as 
promising therapeutics for ATL in the future.
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